---
schema_version: "secwatch.filing_event.v1"
accession: "0001185185-24-000654"
form_type: "8-K/A"
ticker: "BHIC"
cik: "0001784440"
company_name: "BioScience Health Innovations, Inc."
filed_at: "2024-06-25T23:59:59+00:00"
generated_at: "2026-06-01T02:14:36.936063+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Nowtransit completes reverse merger with Best Labs; issues 34M shares (85.4%) for supplement business

## Summary
- Issued 34,371,100 shares (85.39% of post-closing shares) to Best Labs shareholders for all of Best's shares; deal closed March 10, 2023.
- Company exited online delivery business; now markets Be On-Guard mouth spray, nasal spray, surface cleaner, brain support supplements, and methylene blue products.
- Zero employees as of March 13, 2023; supply chain managed by Ageless Holdings LLC (CEO is managing member).
- Filing addresses shell status; company remains OTC Pink voluntary filer, subject to penny stock rules and limited liquidity.
- Holds provisional patent 63/560,474 for methylthioninium salt compositions; plans to file PCT application by March 2024.

## SEC filing metadata
- accession: 0001185185-24-000654
- form_type: 8-K/A
- ticker: BHIC
- cik: 0001784440
- company_name: BioScience Health Innovations, Inc.
- filed_at: 2024-06-25T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 2.01, 5.03, 9.01, 4.01, 3.02, 5.02, 5.06
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1784440/000118518524000654/0001185185-24-000654-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1784440/000118518524000654/nowtransit20240625_8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001185185-24-000654
- JSON: https://secwatch.observer/filing/0001185185-24-000654.json
- Plain text: https://secwatch.observer/filing/0001185185-24-000654.txt

## Key facts
- Executive change
  Darren Lopez was appointed as Director at BioScience Health Innovations, Inc..
  - Action: appointed
  - Role: Director
  source text: Darren Lopez and John Chymboryk were appointed to serve on the Board of Directors with Justin Earl.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1784440/000118518524000654/0001185185-24-000654-index.htm
- Executive change
  Justin Earl resigned as Chief Executive Officer at BioScience Health Innovations, Inc..
  - Action: resigned
  - Role: Chief Executive Officer
  source text: Justin Earl tendered his resignation as the sole officer of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1784440/000118518524000654/0001185185-24-000654-index.htm
- Executive change
  John Chymboryk was appointed as Director at BioScience Health Innovations, Inc..
  - Action: appointed
  - Role: Director
  source text: Darren Lopez and John Chymboryk were appointed to serve on the Board of Directors with Justin Earl.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1784440/000118518524000654/0001185185-24-000654-index.htm
- Executive change
  Darren Lopez was appointed as Chief Executive Officer at BioScience Health Innovations, Inc..
  - Action: appointed
  - Role: Chief Executive Officer
  source text: Darren López was appointed as the Chief Executive Officer of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1784440/000118518524000654/0001185185-24-000654-index.htm
- M&A Transactions
  BioScience Health Innovations, Inc. completed an acquisition involving Best Labs, Inc. for 34,371,100 shares of the Company’s common stock, representing approximately 85.39% of the issued and outstanding shares (closed 2023-03-10).
  - Action: acquisition
  - Counterparty: Best Labs, Inc.
  - Consideration: 34,371,100 shares of the Company’s common stock, representing approximately 85.39% of the issued and outstanding shares
  - Closing: 2023-03-10
  source text: 2023 (the “ Closing ”). As a result of the Exchange Agreement Best became the wholly-owned subsidiary of the Company. Upon the Closing, the Company issued the Best shareholders 34,371,100 shares of the Company’s common stock, representing approximately 85.39% of the issued and outstanding shares of the Company’s common stock following Closing, in exchange for all
  evidence_url: https://www.sec.gov/Archives/edgar/data/1784440/000118518524000654/0001185185-24-000654-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.